DT095435 : a pan group III mGluR PAM candidate ready to enter pre-IND studies

Scroll To Explore

DT095435 : a pan group III mGluR PAM candidate ready to enter pre-IND studies

 

Thanks to its innovative mechanism of action targeting not only mGluR4 but also mGluR7 and 8, and its improved oral PK profile, DT095435 is positioned as a second-generation compound which should succeed to reach significant clinical efficacy where Foliglurax has narrowly failed.